SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-061508
Filing Date
2023-11-09
Accepted
2023-11-09 07:03:11
Documents
80
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q omga-20230930.htm   iXBRL 10-Q 2898236
2 EX-31.1 omga-ex31_1.htm EX-31.1 17920
3 EX-31.2 omga-ex31_2.htm EX-31.2 17675
4 EX-32.1 omga-ex32_1.htm EX-32.1 10216
5 EX-32.2 omga-ex32_2.htm EX-32.2 9955
  Complete submission text file 0000950170-23-061508.txt   10084554

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20230930_pre.xml EX-101.PRE 412787
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT omga-20230930_cal.xml EX-101.CAL 50954
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20230930.xsd EX-101.SCH 74965
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20230930_lab.xml EX-101.LAB 563501
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT omga-20230930_def.xml EX-101.DEF 251744
74 EXTRACTED XBRL INSTANCE DOCUMENT omga-20230930_htm.xml XML 1636296
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40657 | Film No.: 231389998
SIC: 2836 Biological Products, (No Diagnostic Substances)